1333127-02-8

Basic information

• Product Name: N-(5-chloropyridine-2-yl)-2-[(4-methylaminophenylcarbonyl)amino]-5-methylbenzamide
• Synonyms: N-(5-chloropyridine-2-yl)-2-[(4-methylaminophenylcarbonyl)amino]-5-methylbenzamide
• CAS NO: 1333127-02-8
• Molecular Weight: 394.86
• Mol File: 1333127-02-8.mol

Chemical Properties

• CAS DataBase Reference: N-(5-chloropyridine-2-yl)-2-[(4-methylaminophenylcarbonyl)amino]-5-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-chloropyridine-2-yl)-2-[(4-methylaminophenylcarbonyl)amino]-5-methylbenzamide(1333127-02-8)
• EPA Substance Registry System: N-(5-chloropyridine-2-yl)-2-[(4-methylaminophenylcarbonyl)amino]-5-methylbenzamide(1333127-02-8)

Safety Data

• Hazardous Substances Data: 1333127-02-8(Hazardous Substances Data)

Upstream product

• 50734-07-1 4-[N-methyl-N-(trifluoroacetyl)amino]benzoic acid 
• 10541-83-0 N-methyl-p-aminobenzoic acid 
• 280773-05-9 N-(5-chloropyridin-2-yl)-2-amino-5-methylbenzamide 
• 280773-04-8 N-(5-chloro(pyridin-2-yl))(5-methyl-2-nitrophenyl)carboxamide 
• 1072-98-6 5-chloro-2-pyridylamine 
• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 1333127-01-7 N-(5-chloropyridine-2-yl)-2-[(4-methyl(trifluoroacetyl)aminophenylcarbonyl)amino]-5-methylbenzamide 

Downstream Products

• 1333127-36-8 N-(5-chloropyridine-2-yl)-2-[(4-carbamoyl(methyl)aminophenylcarbonyl)amino]-5-methylbenzamide 
• 1333126-80-9 N-(5-chloropyridine-2-yl)-2-[(4-etanimidoil(methyl)aminophenylcarbonyl)amino]-5-methylbenzamide 
• 1333127-37-9 2-[4-carbamimidoylmethylamino]phenylcarbonylamino-N-(5-chloropyridine-2-yl)-5-methylbenzamide 
• 1333126-93-4 2-[4-(methyl(N-methylcarbamimidoyl)-amino)]phenylcarbonylamino-N-(5-chloropyridine-2-yl)-5-methylbenzamide 
• 1333126-92-3 N-(5-chloropyridine-2-yl)-2-[(4-(imino(methoxy)methyl)(methyl)aminophenylcarbonyl)amino]-5-methylbenzamide 

Relevant articles and documents

PHARMACEUTICAL COMPOSITIONS COMPRISING ANTICOAGULANT N-(5-CHLOROPYRIDINE-2-YL)-2-({4-[ETHANIMIDOIL(METHYL)AMINO]BENZOYL}AMINO)-5-METHYLBENZAMIDE

The invention relates to area of medicine, in particular to pharmacology, namely to novel pharmaceutical compositions for oral use for treatment of diseases associated with increased thrombus formation. The compositions comprise the anticoagulant N-(5-chloropyridine-2-yl)-2-({4-[ethanimidoil(methyl)amino]benzoyl}amino)-5-methylbenzamide or a pharmaceutically acceptable salt thereof, being a factor Xa inhibitor and polyprenol, and are protected from the contact with acidic gastric juice by an enteric coating or capsule. The compositions are of high efficacy and bioavailability and can be used to treat and prevent conditions characterized by undesirable thrombosis.

URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA

The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems.